Want to see ATHE full AI Analyst Report?
ATHE Stock Chart & Stats
$4.47
$0.13(2.75%)
At close: 4:00 PM EDT
$4.47
$0.13(2.75%)
Day’s Range― - ―
52-Week Range$2.66 - $5.89
Previous Close$4.56
Volume3.89K
Average Volume (3M)13.54K
Market Cap
$82.78M
Enterprise Value$19.51
Total Cash (Recent Filing)$37.32M
Total Debt (Recent Filing)$193.47K
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Mar 04, 2027EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding18,391,737
10 Day Avg. Volume22,745
30 Day Avg. Volume13,538
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)3.19
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.50Price Target Upside179.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$2.50M
Bulls Say, Bears Say
Bulls Say
ATH434 Intellectual PropertyLong-duration patent protection can preserve future exclusivity for ATH434, improve its strategic value for partnerships, and support commercial potential if Phase 3 and regulatory approval succeed.
FDA-Confirmed Phase 3 PathwayRegulatory alignment reduces uncertainty around trial design, evidence requirements, and the route to a potential filing, making development planning more focused and potentially resource-efficient.
Low Leverage Balance SheetMinimal debt reduces fixed financial obligations and preserves flexibility to fund clinical development, although the benefit is moderated by ongoing operating losses and the need to manage cash carefully.
Bears Say
No Current Revenue And Large LossesThe absence of recurring product revenue leaves the company dependent on clinical success and future financing, while sustained operating losses show that commercial earnings power remains unproven.
Severe Cash BurnPersistently negative and worsening operating cash flow can shorten the funding runway and force additional capital raising, limiting strategic flexibility while Phase 3 activities expand spending.
External Funding And Dilution RiskBecause development operations are not self-funded, future equity issuance may be necessary to finance trials, creating dilution risk and making long-term progress dependent on continued capital-market access.
Alterity Therapeutics News
ATHE FAQ
What was Alterity Therapeutics Ltd’s price range in the past 12 months?
Alterity Therapeutics Ltd lowest stock price was $2.66 and its highest was $5.89 in the past 12 months.
What is Alterity Therapeutics Ltd’s market cap?
Alterity Therapeutics Ltd’s market cap is $82.78M.
When is Alterity Therapeutics Ltd’s upcoming earnings report date?
Alterity Therapeutics Ltd’s upcoming earnings report date is Mar 04, 2027 which is in 181 days.
How were Alterity Therapeutics Ltd’s earnings last quarter?
Alterity Therapeutics Ltd released its earnings results on Feb 25, 2026. The company reported -$0.415 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.165.
Is Alterity Therapeutics Ltd overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Undervalued.
Does Alterity Therapeutics Ltd pay dividends?
Alterity Therapeutics Ltd does not currently pay dividends.
What is Alterity Therapeutics Ltd’s EPS estimate?
Alterity Therapeutics Ltd’s EPS estimate is -0.01.
How many shares outstanding does Alterity Therapeutics Ltd have?
Alterity Therapeutics Ltd has 18,391,737 shares outstanding.
What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?
Alterity Therapeutics Ltd reported an EPS of -$0.415 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went up 2.945%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?
Currently, no hedge funds are holding shares in ATHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.70%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alterity Therapeutics Ltd
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
ATHE Stock 12 Month Forecast
Average Price Target
$12.50
▲(179.64% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.10% Other Institutional Investors
98.90% Public Companies and
Individual Investors